Scholarlink

<p>Ovarian cancer (OC) remains the most lethal gynecologic malignancy due to late-stage diagnosis, high recurrence rates, and chemoresistance. Parthanatos, a distinct caspase-independent form of programmed cell death mediated by poly (ADP-ribose) (PAR), plays a critical role in DNA damage response and tumor progression. In this study, we identified parthanatos-related genes (PRG) associated with OC prognosis based on integrated analyses of TCGA and GEO datasets, and developed a PRG-based risk model with significant prognostic value. Immune infiltration analysis and single-cell RNA sequencing revealed that high-risk patients exhibited a more immunosuppressive tumor microenvironment. Drug sensitivity profiling and clinical subgroup analyses further supported the model’s clinical applicability. Among the screened PRG, TGFBI was selected for experimental validation, and in vitro assays including qRT-PCR, western blotting, colony formation, and Transwell migration demonstrated its role in promoting OC cell proliferation, invasion, and clonogenicity. These findings underscore the prognostic and biological significance of parthanatos in OC and suggest that targeting key PRG such as TGFBI may offer novel therapeutic strategies to improve patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of parthanatos-related molecular subtypes and development of prognostic risk models in ovarian cancer based on multi-omics analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月2日

查看全文
  • Xiaoying Qi,
  • Changqing Jiang,
  • Ning Wang,
  • Yi Han,
  • Tingting Liu,
  • Liying Huang,
  • Guangjie Yin

摘要

Ovarian cancer (OC) remains the most lethal gynecologic malignancy due to late-stage diagnosis, high recurrence rates, and chemoresistance. Parthanatos, a distinct caspase-independent form of programmed cell death mediated by poly (ADP-ribose) (PAR), plays a critical role in DNA damage response and tumor progression. In this study, we identified parthanatos-related genes (PRG) associated with OC prognosis based on integrated analyses of TCGA and GEO datasets, and developed a PRG-based risk model with significant prognostic value. Immune infiltration analysis and single-cell RNA sequencing revealed that high-risk patients exhibited a more immunosuppressive tumor microenvironment. Drug sensitivity profiling and clinical subgroup analyses further supported the model’s clinical applicability. Among the screened PRG, TGFBI was selected for experimental validation, and in vitro assays including qRT-PCR, western blotting, colony formation, and Transwell migration demonstrated its role in promoting OC cell proliferation, invasion, and clonogenicity. These findings underscore the prognostic and biological significance of parthanatos in OC and suggest that targeting key PRG such as TGFBI may offer novel therapeutic strategies to improve patient outcomes.